Sven Weiler

Sven Weiler has more than 20 years’ experience in the pharmaceutical industry. After receiving his PhD at the University of Konstanz, Germany he completed his postdoctoral studies at Scripps Resarch Institute, La Jolla, California, USA, working on the total synthesis of complex natural products. In 1999 Sven joined Novartis as a Medicinal Chemistry lab head in the areas of Arthritis and Bone Metabolism. In 2005, as part of an internal talent rotation program, he became Chemistry Project Team Head in the Autoimmunity, Transplantation and Inflammatory (ATI) disease group, working on Sphingosine-1-phosphate receptor agonists. Upon rotation completion, he stepped into the role of Chemistry Unit Head supporting the Novartis Musculoskeletal Disease Area. Prior to joining Endogena Therapeutics and since 2016, Sven has been in the Head of Chemistry role for Basilea Pharmaceutica with a focus on Oncology and Antibacterials. Sven enjoys the interaction with colleagues from different scientific and cultural backgrounds and likes to apply Medicinal Chemistry in a disease-agnostic fashion to tackle medical challenges.